Shilpa Pharma Lifesciences gets certificate of suitability from EDQM for API, Desmopressin 

Shilpa Pharma Lifesciences Limited, a subsidiary of Shilpa Medicare Limited, has recently informed exchanges that the company got a Certificate of Suitability (CEP) from EDQM for its API, Desmopressin.

Shilpa Pharma Lifesciences manufactures desmopressin, a synthetic peptide used to treat central diabetic insipidus and bedwetting. This CEP highlights Shilpa’s commitment to quality-oriented development and commercial manufacturing capabilities.

Advertisement

Mr. Keshav Bhutada, Executive Director- Shilpa Pharma Lifesciences Limited, said, “We at Shilpa have always been investing in challenging chemical synthesis. With unwavering commitment and belief in our technical capabilities, we have invested in developing a versatile peptide portfolio over past few years and Desmopressin is the first peptide molecule to receive CEP from the European Regulators. This CEP showcases our proficiency in quality-oriented development as well as commercial manufacturing capabilities that meet the expectations of global quality standards paving way for more such products to follow”